New Age Alpha Advisors LLC Acquires New Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

New Age Alpha Advisors LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 2,842 shares of the company’s stock, valued at approximately $177,000.

Other hedge funds have also recently bought and sold shares of the company. Clear Creek Financial Management LLC bought a new stake in shares of TransMedics Group during the fourth quarter worth $352,000. Vaughan Nelson Investment Management L.P. increased its holdings in TransMedics Group by 9.9% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after purchasing an additional 32,605 shares in the last quarter. Baillie Gifford & Co. increased its holdings in TransMedics Group by 14.9% during the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after purchasing an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new stake in shares of TransMedics Group in the fourth quarter valued at about $6,734,000. Finally, Zacks Investment Management acquired a new position in shares of TransMedics Group during the third quarter worth about $1,607,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group reissued a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Robert W. Baird reduced their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Piper Sandler lowered their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $73.11 on Thursday. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of 77.78 and a beta of 2.12. The stock’s 50 day moving average price is $69.76 and its two-hundred day moving average price is $86.43. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.